Brenntag Specialties becomes exclusive distributor for INOFEA services in EMEA
Brenntag announced the exclusive partnership with INOFEA to promote the pharmaceutical applications of its enzyme technology in EMEA.
As part of the exclusive partnership, Brenntag and INOFEA will provide support and services to enable customers to get the most out of INOFEA’s technology in their applications, such as protecting and enhancing the performance of their enzymes. Brenntag will leverage its global reach to promote INOFEA’s products and services within the pharmaceutical industry, including the manufacturers of APIs, biosimilars, intermediates, diagnostics and medical devices.
INOFEA has developed the enzzen® technology, enhancing enzyme stability, enabling recyclability and easy recovery in manufacturing steps. Enzymes earn a broader substrate range and achieve an extraordinary reactivity by enhancing reaction rate and selectivity. Thus, customers need less raw materials for synthesis, less energy during the production process and can benefit from lower waste production and solvents used in biocatalytic processes.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Lumiphore, Inc. - Richmond, USA

Lactate for Brain Energy
List_of_bolete_species
CureVac Receives U.S. Patent Covering Entire Process for Pharmaceutical Manufacturing of RNA
Casting a wide net to fight coronaviruses
Sexual transmission of Ebola likely to impact course of outbreaks
How a protein in your brain could protect against Alzheimer's disease - New research sets the stage for new therapeutic strategies for Alzheimer's disease
New model finds HIV acute phase infectivity may be lower than previously estimated

KNAUER is expanding its business activities into the field of lipid nanoparticle production equipment - In connection with the development of mRNA-based vaccines against Corona, LNPs have shown to be a suitable delivery form
